SCHEMBL6996

SCHEMBL6996

O=C(O)C1CCCN1S(=O)(=O)c1ccccc1

nearest known ligand 0.82

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
HTT P42858 1/20 0.65
MMP2 P08253 2/20 0.62
MMP9 P14780 2/20 0.62
KDM4E B2RXH2 1/20 0.59
HSD17B10 Q99714 1/20 0.59
FKBP1A P62942 2/20 0.59
MMP8 P22894 1/20 0.57
MMP12 P39900 1/20 0.57
MMP13 P45452 1/20 0.57
POLB P06746 1/20 0.57
LMNA P02545 3/20 0.55
MAPT P10636 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
GAA P10253 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6997 1.00 ALDH1A1 (0.65) ALDH1A1HTTMMP2MMP9KDM4E
SCHEMBL23519421 1.00 ALDH1A1 (0.65) ALDH1A1HTTMMP2MMP9KDM4E
Water SCHEMBL28790504 0.98 ALDH1A1 (0.63) ALDH1A1HTTMMP2MMP9KDM4E
SCHEMBL2977278 0.95 ALDH1A1 (0.72) ALDH1A1HTTMMP2MMP9HSD17B10
SCHEMBL1385016 0.95 ALDH1A1 (0.72) ALDH1A1HTTMMP2MMP9HSD17B10
SCHEMBL5702097 0.92 ALDH1A1 (0.58) ALDH1A1HTTMMP2MMP9KDM4E
SCHEMBL5702286 0.92 ALDH1A1 (0.58) ALDH1A1HTTMMP2MMP9KDM4E
SCHEMBL21519741 0.92 ALDH1A1 (0.58) ALDH1A1HTTMMP2MMP9KDM4E
SCHEMBL1750430 0.91 MMP2 (0.76) ALDH1A1HTTMMP2MMP9KDM4E
SCHEMBL4653160 0.91 MMP2 (0.76) ALDH1A1HTTMMP2MMP9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104822267-A INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE BARUCH S BLUMBERG INST 2015-08-05 CN claimed
US-20150038515-A1 INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-05 US claimed
EP-2819671-A2 BINHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE Baruch S. Blumberg Institute (US) 2015-01-07 EP claimed
WO-2013130703-A2 BINHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) 2013-09-06 WO claimed
WO-2011073376-A1 PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) EUROSCREEN S.A. (BE) 2011-06-23 WO claimed
EP-1149099-A2 IMIDAZO[4,5-C]-PYRIDINE-4-ON-DERIVATIVES MERCK PATENT GmbH (DE) 2001-10-31 EP claimed
WO-2000040583-A2 IMIDAZO[4,5-C]-PYRIDINE-4-ON-DERIVATIVES MERCK PATENT GMBH (DE) 2000-07-13 WO claimed
WO-2026103853-A1 TSHR ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF 长春金赛药业有限责任公司 2026-05-21 WO disclosed
WO-2026103887-A1 PROLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 北京康辰药业股份有限公司 2026-05-21 WO disclosed
WO-2026098667-A1 USP30 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF 长春金赛药业有限责任公司 2026-05-15 WO disclosed
CN-117659017-B TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof 北京华益健康药物研究中心 2026-05-15 CN disclosed
CN-122036731-A CB1 receptor inverse agonist compound, pharmaceutical composition, preparation method and application thereof 北京康辰药业股份有限公司 2026-05-15 CN disclosed
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 EP disclosed
WO-1999016751-A1 BENZAMIDINE DERIVATIVES AS FACTOR XA INHIBITORS MERCK PATENT GMBH (DE) 1999-04-08 WO disclosed
WO-1999012924-A1 PIPERIDINYLMETHYLOXAZOLIDINONE DERIVATIVE MERCK PATENT GMBH (DE) 1999-03-18 WO disclosed
EP-0898569-A1 PIPERIDINES AND PYRROLIDINES MERCK PATENT GmbH (DE) 1999-03-03 EP disclosed
WO-1998042702-A1 ENDOTHELIN-RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 1998-10-01 WO disclosed
WO-1998041521-A1 ENDOTHELIN RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 1998-09-24 WO disclosed
WO-1998038189-A1 OXAZOLIDINES AS 5-HT2A-ANTAGONISTS MERCK PATENT GMBH (DE) 1998-09-03 WO disclosed
WO-1997040038-A1 PIPERIDINES AND PYRROLIDINES MERCK PATENT GMBH (DE) 1997-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038515-A1 INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE HAVCR2, PCNA, DNMT1 ALDH1A1 4030/4885HTT 3903/4885MMP2 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.